Quantitative Analysis of the 50% Hemolysis Rate (HC50/CH50): Principles, Methods, and Applications

Quantitative analysis of the 50% hemolysis rate (HC50/CH50) is a laboratory experiment that measures the degree of red blood cell membrane damage caused by medical devices, biomaterials, chemicals, and biological samples. By quantifying hemoglobin release through spectrophotometry, the test generates objective and reproducible data required for biocompatibility evaluation under ISO 10993-4, ASTM F756, and GB/T 16886.4. This article explains the experimental principles, sample types, testing items, analytical methods, and typical applications of the 50% hemolysis quantitative analysis experiment.

Technical Overview

Hemolysis is the rupture of erythrocyte membranes and the subsequent release of hemoglobin into the surrounding medium. When blood contacts a foreign material, device, or chemical agent, membrane-damaging interactions can be quantified because oxyhemoglobin exhibits a characteristic absorption peak at approximately 540 to 545 nm. The absorbance of the supernatant after centrifugation is directly proportional to the amount of hemoglobin released, converting a biological phenomenon into a measurable optical signal.

The "50% hemolysis" endpoint is expressed through several related quantitative parameters:

• Hemolysis rate (%) — the percentage of total hemoglobin released by a test sample relative to a complete-hemolysis positive control, calculated as: Hemolysis rate (%) = (OD_sample − OD_negative control) / (OD_positive control − OD_negative control) × 100%.
• HC50 (50% hemolytic concentration) — the concentration of a test substance that lyses 50% of a standardized erythrocyte suspension, determined from a dose-response curve.
• CH50 (50% complement hemolytic activity) — the dilution or unit quantity of serum complement required to lyse 50% of antibody-sensitized sheep erythrocytes, reflecting total classical pathway complement activity.

Because complement-mediated lysis follows a sigmoidal dose-response relationship, the classical von Krogh equation is used to linearize the curve: log[y/(1 − y)] = n·log(V) + log(K), where y is the fraction of cells lysed and V is the volume of serum. The dilution corresponding to 50% lysis defines one CH50 unit. Under ASTM F756, materials are commonly classified by hemolytic index: approximately 0–2% is considered non-hemolytic, 3–5% slightly hemolytic, and greater than 5% hemolytic, while many regulatory schemes treat a hemolysis rate of 5% or less as acceptable for blood-contacting products.

Testing Samples

Medical Devices and Blood-Contacting Products

Finished devices and device components that contact circulating blood, either directly or indirectly, form the largest sample category. Typical examples include:

• Intravascular catheters, guidewires, cannulae, and introducer sheaths
• Vascular stents, stent delivery systems, and vascular grafts
• Oxygenators, extracorporeal circulation tubing, and blood pumps
• Hemodialyzers, hemoperfusion cartridges, and apheresis sets
• Blood bags, transfusion sets, infusion sets, syringes, and needles
• Heart valves, ventricular assist components, and surface coatings

Biomaterials, Chemicals, and Formulations

The assay also applies to raw and processed materials under development, including polymers, metals, ceramics, hydrogels, and functional coatings; surfactants and cosmetic ingredients; pharmaceutical excipients and solubilizers; and nanoparticle, liposomal, or micellar drug delivery systems evaluated for hemocompatibility under ASTM E2524. Membrane-active research compounds such as antimicrobial peptides and venom components are frequently profiled by HC50 determination.

Clinical and Biological Samples

Human or animal serum specimens submitted for total complement activity (CH50) determination, plasma samples for free hemoglobin quantification, and freshly drawn anticoagulated whole blood serving as the test substrate for hemolysis rate measurements.

Testing Items

Core quantitative endpoints offered in the 50% hemolysis analysis experiment include:

• Hemolysis rate by the direct contact method (%)
• Hemolysis rate by the indirect (material extract) method (%)
• HC50 — concentration of test substance producing 50% hemolysis
• CH50 — total complement hemolytic activity of serum, reported in U/mL or as a dilution
• Hemolytic index classification in accordance with ASTM F756
• Plasma free hemoglobin quantification
• Time-course and dose-response hemolysis profiling

Testing Methods

Sample Preparation and Blood Collection

Fresh anticoagulated blood is collected from healthy donors or animals using heparin or citrate anticoagulation; EDTA is avoided for complement studies because it chelates the divalent cations required for complement activation. For device extracts, sample preparation follows ISO 10993-12, with standardized ratios such as 3 cm²/mL or 6 cm²/mL surface area per extraction volume and extraction conditions commonly set at 37°C for 72 hours, or other justified parameters simulating clinical use.

Direct Contact Method

The test material is placed in direct contact with diluted anticoagulated blood and incubated at 37°C, typically for 30 minutes to 3 hours with gentle agitation to maintain uniform exposure. After incubation, the specimens are removed and the blood is centrifuged to separate intact cells from the hemoglobin-containing supernatant.

Indirect (Extract) Method

The prepared material extract is mixed with diluted blood and incubated at 37°C for a defined period, typically 1 to 3 hours. This approach evaluates leachable substances and is preferred for devices with complex geometries or materials that cannot be immersed uniformly in blood.

Spectrophotometric Quantification

Supernatant absorbance is measured at 540 to 545 nm against an appropriate blank. Drabkin's reagent may be used to convert all hemoglobin species to the stable cyanmethemoglobin form for improved accuracy, with quantification against a certified hemoglobin calibration standard. Each condition is tested at least in triplicate, and the hemolysis rate is calculated from the sample, positive control, and negative control absorbance values.

Determination of HC50 and CH50

For HC50, a geometric dilution series of the test substance is incubated with a standardized erythrocyte suspension, and the concentration causing 50% lysis is derived by linear interpolation between bracketing dilutions or by four-parameter logistic regression of the dose-response curve. For CH50, serial dilutions of serum are incubated with antibody-sensitized sheep erythrocytes; lysis fractions are transformed using the von Krogh equation, and the 50% endpoint is read from the linear portion of the plot. Results are reported as HC50 in mg/mL or µg/mL, or CH50 in U/mL, with laboratory-established reference intervals.

Quality Control and Validity Criteria

Each run includes a positive control (such as 1% Triton X-100, saponin, or sterile distilled water producing complete hemolysis) and a negative control (phosphate-buffered saline or 0.9% sodium chloride). The assay is considered valid when the positive control absorbance falls within the established range, negative control hemolysis remains below the acceptance threshold, and replicate coefficients of variation do not exceed predefined limits. A reference serum of known CH50 activity is included in complement assays.

Applications

Quantitative hemolysis data support decision-making across regulatory, clinical, and research contexts:

• Regulatory biocompatibility evaluation of blood-contacting medical devices under ISO 10993-4 and GB/T 16886.4 for registration submissions
• Research and development screening of hemocompatible polymers, coatings, and surface modification strategies
• Batch release testing and periodic quality control of device production
• Hemocompatibility assessment of nanoparticles, liposomes, and nanomedicines per ASTM E2524
• In vitro screening of surfactants and cosmetic ingredients using the HC50 endpoint as part of irritation assessment strategies
• Clinical laboratory determination of CH50 for diagnosing complement deficiencies and monitoring complement consumption in immune complex diseases
• Evaluation of blood storage containers, transfusion equipment, and extracorporeal circuit components
• Mechanistic studies of membrane-active agents, detergents, peptides, and venoms

FAQ

What is the difference between hemolysis rate, HC50, and CH50?

Hemolysis rate expresses the percentage of hemoglobin released by one material at one condition, typically used for medical device evaluation. HC50 is the concentration of a soluble substance causing 50% lysis of erythrocytes, used for chemicals and formulations. CH50 measures the functional activity of serum complement required for 50% lysis of sensitized erythrocytes, used in clinical immunology.

Which blood source is used?

Rabbit or human anticoagulated blood is commonly used for device hemolysis testing, while sheep erythrocytes sensitized with specific antibody are standard for CH50 complement assays. The chosen species and anticoagulant are documented in the test report and justified relative to the study objective.

What is the acceptance criterion for medical devices?

Although criteria depend on the product standard and intended use, a hemolysis rate of 5% or less is widely accepted as indicating non-hemolytic or acceptable behavior, consistent with the classification bands described in ASTM F756 and the evaluation principles of ISO 10993-4 and GB/T 16886.4.

How is the 50% endpoint calculated?

The 50% endpoint is derived from a dilution or concentration series. Analysts apply either linear interpolation between the two points bracketing 50% lysis, a von Krogh log transformation for complement assays, or four-parameter logistic curve fitting, followed by verification that the experimental points span the 50% level with acceptable precision.

What controls are included in each experiment?

Every experiment includes a complete-hemolysis positive control such as Triton X-100, saponin, or distilled water; a negative control such as saline or phosphate-buffered saline; blank corrections; and, for CH50 assays, a reference serum with assigned activity. Replicate testing and predefined validity criteria ensure data reliability.

How should samples be submitted for testing?

Devices or materials should be supplied in clean, sterile, representative condition in quantities sufficient for extraction or contact testing plus repeats, along with material composition, intended blood contact category, and desired standard. Serum samples for CH50 should be separated promptly, frozen to preserve complement activity, and shipped on dry ice through accredited third-party laboratories or qualified internal biocompatibility facilities with cold-chain documentation.